Here, we demonstrated that chemotherapy regimens that are routinely used in ALL patients decreased the numbers of circulating CD34+ cells and, more specifically, HSCs, and VSELs, but did not affect EPC numbers. Here, CD34 is linked to acute lymphoblastic leukemia.